Research
Monitoring the peptide evidence base as it forms
Trials, pipeline movement, and new publications — recorded with the same prominence whether the result is positive, null, or a discontinuation.
Research
Clinical Trials
How peptide trials are structured, what registry entries tell you, and how to judge a trial before its results appear in the news.
Research
Drug Pipeline
A stage-by-stage view of peptide therapeutics in development, framed by attrition rates rather than press releases.
Research
Emerging Peptides
Compounds attracting scientific attention early, with explicit labelling of how thin the human evidence still is.
Research
Research Tracker
A continuously updated log of notable peptide studies, registry changes, and regulatory filings, each with a status tag.
Research
New Studies
Recent peptide research summarised with design, population, endpoint, and limitation stated up front.
Pipeline
Stage-by-stage view
Development stages
Where peptide science currently sits
Stage indicates how far evaluation has progressed — not likelihood of success. Most candidates entering clinical development never reach approval.
- Preclinical
Next-generation amylin and dual-mechanism candidates
Cell and animal work; no human safety or efficacy data. - Phase 1
Oral peptide delivery platforms
First-in-human safety and pharmacokinetics. - Phase 2
Muscle-preserving co-therapies in weight management
Dose finding with body-composition endpoints. - Phase 3
Triple agonist programmes in obesity and diabetes
Confirmatory efficacy and safety at scale. - Approved
Incretin-based metabolic medicines
Marketed with defined indications and post-marketing surveillance.
Editorial disclaimer
This site is educational and does not provide medical advice, dosing protocols, or treatment recommendations. Regulatory status and evidence strength differ sharply between compounds. A “research use only” label does not indicate that a product is appropriate for human use. Decisions about medicines belong with a qualified clinician.